Jinlei H. Bian

Jiangsu Key Laboratory Of Drug Design And Optimization, P.R. China
Nanjing, 211198, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability.

Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability.

Journal: Journal of medicinal chemistry

Published: March 20, 2026

Wogonin-derived chemotype enables discovery of novel GLS1 inhibitors with potent antitumor activity.

Wogonin-derived chemotype enables discovery of novel GLS1 inhibitors with potent antitumor activity.

Journal: Future medicinal chemistry

Published: March 12, 2026

Discovery and functional characterization of endoglucanases from Coptotermes formosanus with enhanced cellulose hydrolysis via yeast surface display.

Discovery and functional characterization of endoglucanases from Coptotermes formosanus with enhanced cellulose hydrolysis via yeast surface display.

Journal: Applied and environmental microbiology

Published: March 02, 2026

Structure-Informed Design of Distinct Parallel G-Quadruplex Stabilizers for KRAS-Driven Cancer Therapy.

Structure-Informed Design of Distinct Parallel G-Quadruplex Stabilizers for KRAS-Driven Cancer Therapy.

Journal: Angewandte Chemie (International ed. in English)

Published: March 02, 2026

Selective Targeting of STAT6: Recent Advances and Future Perspectives.

Selective Targeting of STAT6: Recent Advances and Future Perspectives.

Journal: Medicinal research reviews

Published: January 18, 2026

New Binding Sites for JAK2 Inhibition in Myeloproliferative Neoplasms: Structural Insights, Therapeutic Potential, and Future Directions.

New Binding Sites for JAK2 Inhibition in Myeloproliferative Neoplasms: Structural Insights, Therapeutic Potential, and Future Directions.

Journal: ChemMedChem

Published: November 26, 2025

Design, synthesis, and pharmacological evaluation of novel isoindoline-based HPK1 degraders.

Design, synthesis, and pharmacological evaluation of novel isoindoline-based HPK1 degraders.

Journal: European journal of medicinal chemistry

Published: October 01, 2025

Correction to "Design, Synthesis, and Biological Evaluation of Sulfonamide Derivatives as Potent CDK9 Inhibitors".

Correction to "Design, Synthesis, and Biological Evaluation of Sulfonamide Derivatives as Potent CDK9 Inhibitors".

Journal: ACS medicinal chemistry letters

Published: September 27, 2025

Discovery of Tricyclic Derivative as Novel and Potent Respiratory Syncytial Virus Fusion Glycoprotein Inhibitor with an Improved Pharmacokinetic Profile.

Discovery of Tricyclic Derivative as Novel and Potent Respiratory Syncytial Virus Fusion Glycoprotein Inhibitor with an Improved Pharmacokinetic Profile.

Journal: Journal of medicinal chemistry

Published: September 11, 2025

A small molecule disrupts G4-STAT1 interaction and synergizes with olaparib to drive cancer cell death.

A small molecule disrupts G4-STAT1 interaction and synergizes with olaparib to drive cancer cell death.

Journal: Nucleic acids research

Published: September 05, 2025

Recent advances in ASCT2 inhibitors: ligand design and therapeutic applications.

Recent advances in ASCT2 inhibitors: ligand design and therapeutic applications.

Journal: Future medicinal chemistry

Published: August 17, 2025

Metabolic engineering of Saccharomyces cerevisiae for de novo biosynthesis of hydroxytyrosol and salidroside.

Metabolic engineering of Saccharomyces cerevisiae for de novo biosynthesis of hydroxytyrosol and salidroside.

Journal: Applied and environmental microbiology

Published: July 16, 2025

Showing 1-12 of 71

Last Updated: 09/26/2026